BIOMAT Database Logo BIOMAT Database Logo

Inhaled platelet-activating factor increases airway sensitivity but not maximal airway narrowing to methacholine in normal subjects. 1994

S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Servizio di Fisiopathologia Respiratoria, G. Di Maria, Ospedale Ascoli-Tomaselli, Catania, Italy.

To examine the effect of inhaled platelet-activating factor (PAF) on airway sensitivity and on maximal airway narrowing, we measured airway response to doubling concentrations of methacholine (MCh) 48 h before and 48 h after inhalation of 10, 50 and 100 micrograms of PAF in six nonatopic, nonasthmatic subjects. The forced expiratory volume in one second (FEV1) and airflow at 30 percent of vital capacity (V30) from partial forced expiration were used to assess changes in airway calibre. Inhalation of PAF caused only minor changes in FEV1. In contrast, inhalation of 100 micrograms of PAF caused a significant fall in V30 from 2.64 +/- 0.35 to 1.35 +/- 0.43 l.min-1 (p < 0.05). Two days after PAF inhalation a leftward shift of the concentration-response curve to MCh was observed. The MCh concentration causing a 20% fall in FEV1 (PC20FEV1) was 11.25 +/- 1.78 and 2.38 +/- 1.29 mg.ml-1 (geometric mean +/- GSEM; p < 0.05) before and after PAF inhalation, respectively. PAF did not affect the maximal airway response to MCh. The maximum percentage fall in FEV1 was 36.2 +/- 1.9% at baseline and 37.6 +/- 1.8% after PAF inhalation. Likewise, maximum percentage change in V30 was 72.8 +/- 3.7% at baseline and 73.6 +/- 3.4% after PAF inhalation. The results of this study show that PAF inhalation increases airway sensitivity without altering the maximal bronchoconstrictive response to MCh in normal subjects.

UI MeSH Term Description Entries
D008297 Male Males
D008448 Maximal Expiratory Flow Rate The airflow rate measured during the first liter expired after the first 200 ml have been exhausted during a FORCED VITAL CAPACITY determination. Common abbreviations are MEFR, FEF 200-1200, and FEF 0.2-1.2. Forced Expiratory Flow 0.2-1.2,Forced Expiratory Flow 200-1200,Flow Rate, Maximal Expiratory,MEFR,Forced Expiratory Flow 0.2 1.2,Forced Expiratory Flow 200 1200
D008449 Maximal Expiratory Flow-Volume Curves Curves depicting MAXIMAL EXPIRATORY FLOW RATE, in liters/second, versus lung inflation, in liters or percentage of lung capacity, during a FORCED VITAL CAPACITY determination. Common abbreviation is MEFV. Maximal Expiratory Flow Volume Curves
D010366 Peak Expiratory Flow Rate Measurement of the maximum rate of airflow attained during a FORCED VITAL CAPACITY determination. Common abbreviations are PEFR and PFR. Expiratory Peak Flow Rate,Flow Rate, Peak Expiratory,PEFR
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D012123 Pulmonary Ventilation The total volume of gas inspired or expired per unit of time, usually measured in liters per minute. Respiratory Airflow,Ventilation Tests,Ventilation, Pulmonary,Expiratory Airflow,Airflow, Expiratory,Airflow, Respiratory,Test, Ventilation,Tests, Ventilation,Ventilation Test
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory

Related Publications

S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine.
October 1987, The American review of respiratory disease,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Tachyphylaxis to inhaled methacholine in normal but not asthmatic subjects.
September 1990, Journal of applied physiology (Bethesda, Md. : 1985),
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects.
January 1991, The American review of respiratory disease,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Airway response to inhaled methacholine in normal human subjects.
September 1993, Pulmonary pharmacology,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
The effect of inhaled budesonide on the maximal degree of airway narrowing to leukotriene D4 and methacholine in normal subjects in vivo.
February 1989, The American review of respiratory disease,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects.
April 1990, The American review of respiratory disease,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Mechanism of airway narrowing caused by inhaled platelet-activating factor. Role of airway microvascular leakage.
June 1991, The American review of respiratory disease,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects.
March 1990, Journal of applied physiology (Bethesda, Md. : 1985),
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
[Effects of inhaled aerosol of platelet activating factor on pulmonary function and airway responsiveness in normal subjects].
August 1992, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
S Bellofiore, and N Ciancio, and A Pennisi, and G Coco, and G Passanisi, and F L Ricciardolo, and S Novo, and G U Di Maria
Comparison of maximal airway narrowing to methacholine between children and adults.
April 1991, The European respiratory journal,
Copied contents to your clipboard!